“Patients with small-cell lung cancer derived no survival benefit from cholesterol-lowering medication, according to a phase 3 randomized, double blind, multicenter, placebo-controlled study published in Journal of Oncology.
” ‘There’s no reason for people to stop taking statins to manage their cholesterol, but it’s extremely unlikely, for patients with small-cell lung cancer, that taking statins will make any difference to their cancer treatment outcome,’ Michael J. Seckl, MD, professor of molecular cancer medicine at Imperial College London, said in a press release. ‘Because all statins work in a similar way to lower cholesterol, it’s relatively unlikely that statins other than pravastatin would have a different, more beneficial effect.’ ”
“A diagnosis of high cholesterol is associated with reduced mortality and improved survival in the four most common cancers, according to research presented today at Frontiers in CardioVascular Biology (FCVB) 2016. The 14 year study from nearly one million patients found that a high cholesterol diagnosis was associated with lower risk of death in lung, breast, prostate and bowel cancers.”
Do you have questions about this story? Let us know in a comment below. If you’re wondering whether this story applies to your own cancer case or a loved one’s, we invite you to use our Ask Cancer Commons service.
“Cholesterol-lowering statin drugs may slow down prostate cancer in men who are also taking medication to reduce their levels of male hormones, according to new research.
“Taking a statin alongside androgen deprivation therapy slowed the progress of prostate cancer by about 10 months, said the study’s lead author, Dr. Lauren Christine Harshman, an assistant professor at Dana-Farber Cancer Institute and Harvard Medical School.
” ‘Patients on a statin have a significantly longer time to progression,’ Harshman said.
“The study’s findings were presented recently at a meeting of the American Society of Clinical Oncology (ASCO) in Orlando, Fla. Research presented at meetings is generally viewed as preliminary until published in a peer-reviewed journal.
“The study did not prove a cause-and-effect link between statins and prostate cancer survival, just an association.”
“Higher levels of total cholesterol and triglycerides, two types of fat, in the blood of men who underwent surgery for prostate cancer, were associated with increased risk for disease recurrence, according to a study published in Cancer Epidemiology, Biomarkers Prevention, a journal of the American Association for Cancer Research.
” ‘While laboratory studies support an important role for cholesterol in prostate cancer, population-based evidence linking cholesterol and prostate cancer is mixed,’ said Emma Allott, PhD, postdoctoral associate at Duke University School of Medicine in Durham, North Carolina. ‘Understanding associations between obesity, cholesterol, and prostate cancer is important given that cholesterol levels are readily modifiable with diet and/or statin use, and could therefore have important, practical implications for prostate cancer prevention and treatment.
” ‘Our findings suggest that normalization, or even partial normalization, of serum lipid levels among men with dyslipidemia [abnormal lipid profile] may reduce the risk of prostate cancer recurrence,’ said Allott.”
“The findings could help explain why taking statins – commonly used cholesterol-lowering drugs – is thought to slow the progress of the disease in some cases.
“The scientists, from The University of Manchester, made the discovery by combining prostate cancer cells in the lab with arachidonic acid (AA), an omega-6 fatty acid that has been shown to attract prostate cancer cells to the bone marrow, where it is found naturally in high concentrations.”
For many years it has been known that cancer cells store and use fat molecules differently from the way normal cells do. Fat molecules, also called lipids, tend to accumulate in so-called lipid droplets within cells. These droplets can be seen under a microscope with special staining methods, but the precise mixture of the different kinds of lipids in an individual cell is difficult to analyze. Now, researchers have developed a new imaging technique called Raman spectromicroscopy, which allows for detailed analysis of lipids on a single-cell level. Continue reading…
“A link between prostate cancer aggressiveness and the accumulation of a compound produced when cholesterol is metabolized in cells has been discovered, findings that could bring new diagnostic and treatment methods. Findings also suggest that a class of drugs previously developed to treat atherosclerosis might be repurposed for treatment of advanced prostate cancer. The research involved analysis of clinical samples harvested from prostate cancer patients, specialized cell lines and mice.”
Geybels MS, Wright JL, Holt SK, Kolb S, et al. The Prostate. Apr 30, 2013.
“We investigated associations between statin use begun before prostate cancer (PCa) diagnosis and PCa recurrence/progression and PCa-specific mortality (PCSM) in a prospective, population-based cohort study…”